Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6146 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Dan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Atorvastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lung Transplantation, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Atorvastatin is a widely prescribed cholesterol‐lowering drug that inhibits 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase to reduce lipid levels. This study aimed to establish a population pharmacokinetic and pharmacodynamic model for atorvastatin in Chinese lung transplant recipients (LTRs), particularly those using voriconazole (VOR) and with different genotypes. It evaluated precise dosing regimens and analyzed the correlation between atorvastatin exposure and clinical outcomes. A nonlinear mixed‐effects model was used for the population pharmacokinetic/pharmacodynamic (PK/PD) analysis. A one‐compartment population PK model was developed, incorporating VOR, SLCO2A1 rs76906503, and SLC22A8 rs2187383 to assess apparent clearance and volume of distribution. LDL‐C was modeled as a biomarker to evaluate atorvastatin efficacy. A Monte Carlo simulation was conducted to assess various dosing schemes and the effects of different covariates on achieving the target LDL concentration. The correlation between atorvastatin exposure and clinical outcomes was also evaluated. Results indicated that the average probability of target attainment for optimal dosing regimens across various covariate results exceeded 45.8%. Dosages of 10, 20, and 40 mg were deemed suitable for LTRs. A lower dose was recommended for LTRs taking VOR or with mutant‐type genotypes to avoid overexposure and adverse reactions. The population PK/PD model offers valuable guidance for evaluating atorvastatin dosing regimens in clinical settings, particularly for LTRs using VOR and those with different genotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
ORCID-Profile: Dan Zhang
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Zhang, D., Du, W., Qin, W., Chen, W., Li, P., & Wang, X. (2025). Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6146
Vancouver
Zhang D, Du W, Qin W, Chen W, Li P, Wang X. Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6146
BibTeX
@article{Zhang2025,
author = {Zhang, Dan and Du, Wenwen and Qin, Wei and Chen, Wenqian and Li, Pengmei and Wang, Xiaoxing},
title = {Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6146}
}
EUVIMED